priorix
glaxosmithkline biologicals s.a. - gyvas susilpnintas schwarz padermės tymų virusas/gyvas susilpnintas rit 4385 padermės kiaulytės virusas (išvestas iš jeryl lynn padermės)/gyvas susilpnintas wistar ra 27/3 padermės raudonukės virusas - milteliai ir tirpiklis injekciniam tirpalui - >= 10(x3) ccid50/>= 10(x3,7) ccid50/>= 10(x3) ccid50/dozėje; >=10(x3) ccid50/>=10(x3,7) ccid50/>=10(x3) ccid50/dozėje; >= 10( - measles, combinations with parotitis and rubella, live attenuated
tetraxim
sanofi pasteur - difterijos anatoksinas/stabligės anatoksinas/bordetella pertussis antigenai: kokliušo anatoksinas/filamentinis hemagliutininas/inaktyvuotas 1-ojo tipo poliovirusas/inaktyvuotas 2-ojo tipo poliovirusas/inaktyvuotas 3-ojo tipo poliovirusas - injekcinė suspensija užpildytame švirkšte - >=20 tv/>=40 tv/25 µg/25 µg/29 dagv/7 dagv/26 dagv/0,5 ml; >=30 tv/>=40 tv/25 µg/25 µg/40 dagv/8 dagv/32 dagv/0,5 ml; >=30 tv - diphtheria-pertussis-poliomyelitis-tetanus
varivax
merck sharp & dohme b.v. - gyvas susilpnintas vėjaraupių virusas (oka/merck padermės) - milteliai ir tirpiklis injekcinei suspensijai užpildytame švirkšte - 1350 pfv/dozėje - varicella, live attenuated
benemicin
tarchomińskie zakłady farmaceutyczne „polfa” spółka akcyjna - rifampicinas - kietosios kapsulės - 300 mg; 150 mg - rifampicin
broncho-munal
sandoz d.d. - liofilizuotas bakterijų lizatas - kietosios kapsulės - 7 mg - other respiratory system products
broncho-munal p
sandoz d.d. - liofilizuotas bakterijų lizatas - kietosios kapsulės - 3,5 mg - other respiratory system products
doxitin
vitabalans oy - doksiciklinas - tabletės - 150 mg; 100 mg - doxycycline
ultomiris
alexion europe sas - ravulizumab - hemoglobinurija, paroksizminis - selektyvūs imunosupresantai - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
quofenix
a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - bendrijos įsigyjamos infekcijos - antibacterials sisteminio naudojimo, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 ir 5. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.
oxy-100, 100 mg/ml injekcinis tirpalas galvijams, veršeliams, avims, ožkoms ir kiaulėms
uab "interchemie werken "de adelaar" lt" (lietuva) - injekcinis tirpalas - 1 ml yra: oksitetraciklino (oksitetraciklino hidrochlorido) - 100,0 mg, pagalbinių medžiagų. - veršeliams, galvijams, avims, ožkoms ir kiaulėms gydyti, sergant artritu, virškinimo trakto ir kvėpavimo takų infekcinėmis ligomis, sukeltomis oksitetraciklinui jautrių bakterijų, pvz., bordetella, campylobacter, chlamydia, e. coli, haemophilus, mycoplasma, pasteurella, rickettsia, salmonella, staphylococcus ir streptococcus spp.